Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Advanced cervical cancer, particularly in its recurrent ... 2015 to early 2020 found that while immunotherapy, particularly pembrolizumab, has gained traction as a second-line treatment option ...

Keytruda (pembrolizumab) has been approved for use in combination with chemoradiotherapy (CRT) for patients with high-risk locally advanced cervical cancer; in other words, those with stage III to ...

Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells ... PD-1 inhibitor Keytruda (pembrolizumab).

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer. A ...

Dr. Wen Chay Yee presented the Asian subgroup analyses data from the KEYNOTE-A18 study, showing that pembrolizumab plus chemotherapy for high-risk locally advanced cervical cancer achieved consistent ...

Pembrolizumab is under clinical development by Merck and ... more prior lines of therapy and for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or ...

and advanced cervical cancer Pragmatica-Lung highlights the importance of asking impactful questions. Is the combination of ramucirumab to pembrolizumab in previously treated patients with stage IV ...